ASN: Model Predicts Benefit of SGLT2 Inhibitors for Adults With T1DM
MONDAY, Nov. 15, 2021 (HealthDay News) — Treatment with sodium-glucose cotransporter 2...
Breaking Nephrology
History of Preeclampsia Is a Risk Factor for Acute Kidney Injury
“Hypertensive disorders of pregnancy—specifically gestational hypertension and preeclampsia—are...
How Question Wording & Setting Impacts CKD Awareness
More than 30 million adults in the United States are affected by CKD, but studies during the past...
Kidney Function in Newly Diagnosed Diabetes: The Role of Community Socioeconomic Deprivation
Throughout the world, 40% to 50% of people with diabetes will develop diabetes-related kidney...
Presentation of Multisystem Inflammatory Syndrome Varies in Adults
THURSDAY, May 20, 2021 (HealthDay News) — Patients with multisystem inflammatory syndrome in...
Smartphone App Improves Kidney Transplant Outcomes
FRIDAY, May 14, 2021 (HealthDay News) — A pharmacist-led smartphone health app prevents...
Assessing Pediatric Immunization Practices in Nephrotic Syndrome
In the current era of the COVID-19 pandemic, understanding barriers to vaccinations in...
Dapagliflozin Gets FDA Nod For Treatment of CKD
New indication expands the use of the oral diabetes drug Dapagliflozin (Farxiga) won FDA approval for use for patients with chronic kidney disease who are at risk of disease progression. The oral tablets showed efficacy in a...
Transient Improvement Found in Sedentary Time in CKD With Intervention
MONDAY, April 26, 2021 (HealthDay News) — An intervention to reduce sedentary time and...
Assessing the Associations Between Blood Pressure Variability, Diuretics & Cardiovascular Events in Patients With CKD
“Patients with CKD have disproportionately high cardiovascular (CV) risk,” explains L. Parker...
Mortality Risk Up for Dialysis Patients in March to July 2020
FRIDAY, April 9, 2021 (HealthDay News) — Patients undergoing dialysis and those with kidney...
Hope for PH1 Patients: Investigational Lumasiran Normalizes Urinary Oxalate Excretion
ILLUMINATE-A study results show efficacy, safety of lumasiran in patients with primary hyperoxaluria type 1 (PH1) In patients with primary hyperoxaluria type 1 (PH1), treatment with lumasiran—an RNA interference...
